OVAS 22.58 Ovascience Inc $OVAS Hit a 52 week high of 22.98 Currently at 22.58 +0.62 +2.82% With a day low of 22.26 and a total volume of 25,869.
OVAS Ovascience Inc Recent Headline News
OvaScience to Participate in Partnering for Cures Conference
Business Wire - Tue Nov 11, 7:30AM CST
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will participate in the Partnering for Cures meeting, an event convened by the Milken Institute's FasterCures. OvaScience will be part of a panel titled, "Collaborative Capital," on November 18, 2014 at 11:00 a.m. ET at the Grand Hyatt New York. Partnering for Cures brings together decision-makers from across diseases and all sectors of medical research to foster collaborations needed to speed up and improve outcomes-driven research and development.
OVAS: 24.19 (+2.23)
OvaScience misses by $0.09
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:03AM CST
OVAS: 24.19 (+2.23)
OvaScience Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:30AM CST
OvaScience(SM) (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported third quarter 2014 financial results.
OVAS: 24.19 (+2.23)
Will OvaScience (OVAS) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:27AM CDT
Will OvaScience (OVAS) Continue to Surge Higher?
OVAS: 24.19 (+2.23)
Why You Shouldn't Bet Against OvaScience (OVAS) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:48AM CDT
OvaScience is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OVAS: 24.19 (+2.23)
OvaScience CEO Michelle Dipp Named Outstanding Young Leader
Business Wire - Thu Sep 18, 9:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today Michelle Dipp, M.D, Ph.D., Chief Executive Officer at OvaScience, has received the Ten Outstanding Young Leaders (TOYL) Award from the Greater Boston Chamber of Commerce.
OVAS: 24.19 (+2.23)
OvaScience Appoints Jeffrey Young to Chief Financial Officer
Business Wire - Thu Sep 18, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions.
OVAS: 24.19 (+2.23)
Earnings Estimates Moving Higher for OvaScience (OVAS): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:45AM CDT
OvaScience's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
OVAS: 24.19 (+2.23)
OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference
Business Wire - Wed Sep 03, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 10, 2014 at 10:25 am ET at the New York Palace Hotel.
OVAS: 24.19 (+2.23)
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 8:39AM CDT
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose roughly 7% on the day.
CBM: 23.46 (+0.50), OVAS: 24.19 (+2.23), GILD: 108.18 (+1.16)
Intrexon Launches Leadership Platform in Bovine Genetics
PR Newswire - Mon Aug 11, 7:30AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies. Trans Ova, as a wholly owned subsidiary of Intrexon, will continue to provide the same level of professional service and dedication to its customers operating under the leadership of David Faber, D.V.M., President, and his management team. Under the terms of the agreement, Trans Ova stockholders received $60 million in cash, $30 million in Intrexon common stock, and $20 million in deferred payments to be paid in three equal installments upon the first, second, and third anniversaries of the closing date.
OVAS: 24.19 (+2.23), XON: 23.14 (+1.54)
OvaScience Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 07, 8:37AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported second quarter 2014 financial results and highlighted recent accomplishments.
OVAS: 24.19 (+2.23)
OvaScience to Present at the Wedbush Life Sciences Management Access Conference
Business Wire - Wed Aug 06, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 8:35 am ET at Le Parker Meridian in New York.
OVAS: 24.19 (+2.23)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving OvaScience, Inc. and a Lead Plaintiff Deadline of August 5, 2014 -- OVAS
GlobeNewswire - Tue Jul 29, 11:35AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company"
(Nasdaq:OVAS) securities between February 25, 2013 and September 10, 2013.
OVAS: 24.19 (+2.23)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against OvaScience, Inc.
Business Wire - Tue Jul 29, 10:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of OvaScience, Inc. ("OvaScience" or the "Company" (NASDAQ:OVAS) that all purchasers of the Company's common stock between February 25, 2013 and September 10, 2013, inclusive (the "Class Period", have until August 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OVAS: 24.19 (+2.23)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Jul 29, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
OVAS: 24.19 (+2.23), QRE: 15.59 (unch), TBBK: 9.40 (+0.05), TRLA: 46.10 (+0.89), FDO: 78.53 (+0.03)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against OvaScience, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of August 5, 2014 -- OVAS
PR Newswire - Mon Jul 21, 4:48PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company" (NasdaqGM: OVAS) securities between February 25, 2013 and September 10, 2013.
OVAS: 24.19 (+2.23)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in OvaScience, Inc. of Class Action Lawsuit and Upcoming Deadline -- OVAS
GlobeNewswire - Sun Jul 20, 4:00AM CDT
Pomerantz LLP has filed a class action lawsuit against OvaScience, Inc ("OvaScience" or the "Company" (Nasdaq:OVAS) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 1:14-cv-12412-DJC, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of OvaScience between February 25, 2013 and September 10, 2013 both dates inclusive (the "Class Period". This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
OVAS: 24.19 (+2.23)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against OvaScience, Inc.
Business Wire - Thu Jul 17, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of OvaScience, Inc. ("OvaScience" or the "Company" (NASDAQ:OVAS) between February 25, 2013 and September 10, 2013, inclusive (the "Class Period" have until August 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OVAS: 24.19 (+2.23)
OVAS Ovascience Inc Recent Headline News
OvaScience to Participate in Partnering for Cures Conference
Business Wire - Tue Nov 11, 7:30AM CST
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will participate in the Partnering for Cures meeting, an event convened by the Milken Institute's FasterCures. OvaScience will be part of a panel titled, "Collaborative Capital," on November 18, 2014 at 11:00 a.m. ET at the Grand Hyatt New York. Partnering for Cures brings together decision-makers from across diseases and all sectors of medical research to foster collaborations needed to speed up and improve outcomes-driven research and development.
OVAS: 24.19 (+2.23)
OvaScience misses by $0.09
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:03AM CST
OVAS: 24.19 (+2.23)
OvaScience Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:30AM CST
OvaScience(SM) (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported third quarter 2014 financial results.
OVAS: 24.19 (+2.23)
Will OvaScience (OVAS) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 8:27AM CDT
Will OvaScience (OVAS) Continue to Surge Higher?
OVAS: 24.19 (+2.23)
Why You Shouldn't Bet Against OvaScience (OVAS) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 7:48AM CDT
OvaScience is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OVAS: 24.19 (+2.23)
OvaScience CEO Michelle Dipp Named Outstanding Young Leader
Business Wire - Thu Sep 18, 9:00AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today Michelle Dipp, M.D, Ph.D., Chief Executive Officer at OvaScience, has received the Ten Outstanding Young Leaders (TOYL) Award from the Greater Boston Chamber of Commerce.
OVAS: 24.19 (+2.23)
OvaScience Appoints Jeffrey Young to Chief Financial Officer
Business Wire - Thu Sep 18, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the appointment of Jeffrey Young to Chief Financial Officer. Mr. Young joins OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions.
OVAS: 24.19 (+2.23)
Earnings Estimates Moving Higher for OvaScience (OVAS): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:45AM CDT
OvaScience's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
OVAS: 24.19 (+2.23)
OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference
Business Wire - Wed Sep 03, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Rodman & Renshaw 16th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., on Wednesday, September 10, 2014 at 10:25 am ET at the New York Palace Hotel.
OVAS: 24.19 (+2.23)
OvaScience (OVAS) Shows Strength: Stock Up 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 8:39AM CDT
OvaScience, Inc. (OVAS) was a big mover last session, as its shares rose roughly 7% on the day.
CBM: 23.46 (+0.50), OVAS: 24.19 (+2.23), GILD: 108.18 (+1.16)
Intrexon Launches Leadership Platform in Bovine Genetics
PR Newswire - Mon Aug 11, 7:30AM CDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies. Trans Ova, as a wholly owned subsidiary of Intrexon, will continue to provide the same level of professional service and dedication to its customers operating under the leadership of David Faber, D.V.M., President, and his management team. Under the terms of the agreement, Trans Ova stockholders received $60 million in cash, $30 million in Intrexon common stock, and $20 million in deferred payments to be paid in three equal installments upon the first, second, and third anniversaries of the closing date.
OVAS: 24.19 (+2.23), XON: 23.14 (+1.54)
OvaScience Reports Second Quarter 2014 Financial Results
Business Wire - Thu Aug 07, 8:37AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported second quarter 2014 financial results and highlighted recent accomplishments.
OVAS: 24.19 (+2.23)
OvaScience to Present at the Wedbush Life Sciences Management Access Conference
Business Wire - Wed Aug 06, 7:30AM CDT
OvaScience(SM) (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 13, 2014 at 8:35 am ET at Le Parker Meridian in New York.
OVAS: 24.19 (+2.23)
UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving OvaScience, Inc. and a Lead Plaintiff Deadline of August 5, 2014 -- OVAS
GlobeNewswire - Tue Jul 29, 11:35AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company"
(Nasdaq:OVAS) securities between February 25, 2013 and September 10, 2013. OVAS: 24.19 (+2.23)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against OvaScience, Inc.
Business Wire - Tue Jul 29, 10:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of OvaScience, Inc. ("OvaScience" or the "Company"
(NASDAQ:OVAS) that all purchasers of the Company's common stock between February 25, 2013 and September 10, 2013, inclusive (the "Class Period", have until August 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. OVAS: 24.19 (+2.23)
Law Offices of Marc S. Henzel Announces Securities Class Action Periods
PR Newswire - Tue Jul 29, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com) a firm focusing on shareholder litigation, gives notice to purchasers of the following securities for the following class periods:
OVAS: 24.19 (+2.23), QRE: 15.59 (unch), TBBK: 9.40 (+0.05), TRLA: 46.10 (+0.89), FDO: 78.53 (+0.03)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Investors of Class Action Against OvaScience, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of August 5, 2014 -- OVAS
PR Newswire - Mon Jul 21, 4:48PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company"
(NasdaqGM: OVAS) securities between February 25, 2013 and September 10, 2013. OVAS: 24.19 (+2.23)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in OvaScience, Inc. of Class Action Lawsuit and Upcoming Deadline -- OVAS
GlobeNewswire - Sun Jul 20, 4:00AM CDT
Pomerantz LLP has filed a class action lawsuit against OvaScience, Inc ("OvaScience" or the "Company"
(Nasdaq:OVAS) and certain of its officers. The class action, filed in United States District Court, District of Massachusetts, and docketed under 1:14-cv-12412-DJC, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of OvaScience between February 25, 2013 and September 10, 2013 both dates inclusive (the "Class Period". This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. OVAS: 24.19 (+2.23)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against OvaScience, Inc.
Business Wire - Thu Jul 17, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of OvaScience, Inc. ("OvaScience" or the "Company"
(NASDAQ:OVAS) between February 25, 2013 and September 10, 2013, inclusive (the "Class Period" have until August 5, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. OVAS: 24.19 (+2.23)
